| Date | Time | Source | Headline | Symbol | Company |
| 07/01/2024 | 1:53AM | Alliance News |  US bases in Europe on high alert amid possible terror threat | | |
| 07/01/2024 | 1:50AM | Alliance News | Airbus says will buy "major activities" of subcontractor Spirit | | |
| 07/01/2024 | 1:49AM | Alliance News | LONDON MARKET EARLY CALL: FTSE 100 called up on week of UK election | | |
| 07/01/2024 | 1:49AM | Business Wire | MOGAS signe un contrat pour soutenir la nouvelle technologie TC2C™ | | |
| 07/01/2024 | 1:49AM | Business Wire | モガス、TC2C™新技術のサポート契約を獲得 | | |
| 07/01/2024 | 1:49AM | Business Wire | MOGAS erhält Auftrag zur Unterstützung der neuen TC2C™-Technologie | | |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Wendel joins Providence to support Globeducate, a leading international K-12 education group, through its next phase of growth | TG:WIS | Wendel SA |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Wendel et Providence accompagneront conjointement Globeducate, un groupe d’écoles internationales de la maternelle au secondaire, dans sa prochaine phase de croissance | EU:MF | Wendel SA |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Wendel joins Providence to support Globeducate, a leading international K-12 education group, through its next phase of growth | EU:MF | Wendel SA |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Wendel et Providence accompagneront conjointement Globeducate, un groupe d’écoles internationales de la maternelle au secondaire, dans sa prochaine phase de croissance | TG:WIS | Wendel SA |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Sword Group: Acquisitions in the UK | TG:9RS | Sword Group |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Sword Group: Acquisitions in the UK | EU:SWP | Sword Group |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Sword Group : Acquisitions en Grande-Bretagne | EU:SWP | Sword Group |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Sword Group : Acquisitions en Grande-Bretagne | LSE:0MN5 | Sword Group Se |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Sword Group : Acquisitions en Grande-Bretagne | TG:9RS | Sword Group |
| 07/01/2024 | 1:45AM | GlobeNewswire Inc. | Sword Group: Acquisitions in the UK | LSE:0MN5 | Sword Group Se |
| 07/01/2024 | 1:38AM | Alliance News | Irish slowdown in manufacturing accelerates in June; outlook positive | | |
| 07/01/2024 | 1:33AM | PR Newswire (US) | Global Times: CPC members reach 99.185 million | | |
| 07/01/2024 | 1:31AM | GlobeNewswire Inc. | Kalmar’s financial information in 2024 | | |
| 07/01/2024 | 1:30AM | Alliance News | GET READY: Induction Healthcare Group, Porvair at 0700 BST | LSE:INHC | Induction Healthcare Group Plc |
| 07/01/2024 | 1:30AM | Alliance News | GET READY: Induction Healthcare Group, Porvair at 0700 BST | LSE:PRV | Porvair Plc |
| 07/01/2024 | 1:30AM | Alliance News | Alliance News UK - start of day | | |
| 07/01/2024 | 1:30AM | GlobeNewswire Inc. | OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ | EU:OSE | OSE Immunotherapeutics |
| 07/01/2024 | 1:30AM | GlobeNewswire Inc. | OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ | LSE:0RAD | Ose Immunotherapeutics Sa |
| 07/01/2024 | 1:30AM | GlobeNewswire Inc. | OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ | EU:OSE | OSE Immunotherapeutics |
| 07/01/2024 | 1:30AM | GlobeNewswire Inc. | OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ | LSE:0RAD | Ose Immunotherapeutics Sa |
| 07/01/2024 | 1:30AM | GlobeNewswire Inc. | OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ | TG:6OP | OSE Immunotherapeutics |
| 07/01/2024 | 1:30AM | GlobeNewswire Inc. | OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ | EU:OSE | OSE Immunotherapeutics |
| 07/01/2024 | 1:30AM | GlobeNewswire Inc. | OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ | TG:6OP | OSE Immunotherapeutics |
| 07/01/2024 | 1:30AM | GlobeNewswire Inc. | BGHL (GBP): NAV(s) | LSE:BGHS | Boussard & Gavaudan Holding Limited |